Hobaneng ha IV ho Subcutaneous Peptide Manufacturing Shift e Ngola hape Tlhaloso ea Sethethefatsi
Ho tsamaisa peptide ho tloha ho intravenous ho ea ho subcutaneous tsamaiso ha se phetoho ea sesebelisoa. Ke phetoho ea tlhaloso eo molek'hule e lokelang ho kopana le eona.
Lebaka ke molumo. Ho tšeloa ka methapo ho ka fana ka molumo o moholo ka nako e tlase, kahoo ha ho mohla tlhahiso e lokelang ho tsepamisoa. Ho fana ka subcutaneous ho tlameha ho lekana lethal dose le lekanang le molumo o monyane oa ente, 'me molumo oo o monyenyane ke moo litšitiso li qalang (Subcutaneous Reka Phano ea High-Dose/Volume Biologics, 2021). Tloaelo e tloaelehileng ea subcutaneous e ne e lekanyelitsoe ho metsi a mangata a 1 ho 2 mL, e atolositsoeng haufinyane ho isa ho hoo e ka bang 3 mL, kahoo tekanyo e tsitsitseng e tlameha ho petetsoa karolong ea sebaka sa IV se lumelletsoeng (Phano ea Subcutaneous ea High-Dose/Volume Biologics, 2021).
Peptide Synthesis Phetoho e tsamaisoa ke moruo oa lenaneo joalo ka khetho ea mokuli: ho itaola lapeng, ho fokotsa ts'epo ho lisebelisoa tsa infusion, phokotso ea litšenyehelo, ho latela le khatello ea molefi mananeo ohle a sutumelletsang litseleng tse tlase (Mokhoa o Mocha oa ho Lokisetsa Peptide Nanosuspensions e tsitsitseng e phahameng ea Concentration, 2023).
Eo ke sephetho sa ts'ebetso ea ntlafatso. Tatelano, mofuta oa letsoai le pheletso ea tlhoekiso joale li rua litšitiso tseo li neng li sa rereloa khahlanong le tsona.
E hlileng e batloang ke Phetoho ea Tsela
Tlhokomeliso e hlokahalang ha se khetho ea tlhahiso. Ke lipalo: boima ba tekanyo bo arotsoe ka molumo oa ente. Hobane sesebelisoa se lokisa molumo, sesebelisoa se lokisa mahloriso, 'me motsoako o phahameng oa peptide o rua palo eo pele ho khethoa mothusi ofe kapa ofe.
E sebedise ka lenaneo la hau. A 100 mg tekanyo e fanoa 1.0 mL e hloka 100 mg/mL. E tšoanang lethal dose ka 0.5 mL e hloka 200 mg/mL. Ha ho letho ka molek’hule le ileng la fetoha lipakeng tsa linomoro tseo tse peli, feela bophahamo ba modumo sesebelisoa se ka fana ka.
Siling eo ea molumo e tiile. A 2023 tlhahlobo ea li-peptide nanosuspensions tse phahameng haholo li bontša hore liente tsa subcutaneous li lekanyelitsoe ho tekanyo ea tekanyo ea 1-1.5 mL., e ka bakang likhakanyo tsa litekanyetso tsa peptide ka holimo 100 mg/mL. A 2021 tlhahlobo ea biologics ea subcutaneous ea tekanyo e phahameng e hlalosa mefuta e tloaelehileng ea subcutaneous ea 1-2 mL., ha a 2024 tlhahlobo ea liente tsa subcutaneous tse ngata li tlaleha hore 2.0 mL ka kakaretso e amoheloa e le ntho e ka khonehang 'me e sebetsa khoebong ka li-autoinjectors tse tšoaroang ka letsoho.
Mekhahlelo e 'meli ha e tseko e tšoanang. Palo ea 1-2 mL e hlalosa hore na lisebelisoa tsa setso li fane ka eng; palo ea 1-1.5 mL ke moeli oa ho sebetsa oo pampiri ea peptide e o nkang ha e fumana lintlha tse kaholimo. 100 mg/mL. Rera khahlanong le e thata ho fihlela sesebelisoa sa hau se tiisitsoe.
Li-peptide tsa Solubility Ceiling li Otla Pele Li-antibodies li Etsa
Nahana ka fensetere e ka sebelisoang e le monyako: bophara bakeng sa selwantsha-mogare se tlwaelehileng, e tšesaane bakeng sa peptide, 'me monyako oa peptide o boetse oa tsamaea ha pH e ntse e fetoha.
Hangata li-peptide li bonts'a ho qhibiliha ho itšetlehileng ka pH hoo li-buffer li sitoang ho li laola hantle, eleng sona se etsang hore ho be thata ho bopa metsi ka bongata bo boholo. Masala a Hydrophobic a na le phello e kholo ka mokhoa o sa lekanyetsoang ho solubility hobane khaello ea sebopeho se matla sa bobeli se a siea a pepesitsoe holimo. (Mokhoa o Mocha oa ho Lokisetsa Peptide Nanosuspensions e tsitsitseng e phahameng ea Concentration, 2023). Sethibela-mafu se epela liketane tseo tse mahlakoreng ka har'a mokokotlo o mennoeng; peptide e khuts'oane ha e na moo e ka li behang teng, kahoo mesaletsa e tšoanang e tsamaisang potency le eona e khanna boikopanyo. Ena ke lekhalo le sebetsang la ho qhibiliha ha peptide le ho lumellana ha li-excipient: "buffer" e ts'oereng lesole la 'mele tharollong e kanna ea se be le peptide, 'me ho hlōleha hangata ho itšetlehile ka pH ho e-na le ho tsamaea butle.
Boholo bo itšetlehile ka tatelano, kahoo tšoara sena e le mokhoa o akaretsang ho e-na le palo e boletsoeng esale pele. Leano la li-antibody tse matla haholo, liente ka holimo 100 mg/mL e sebelisetsoang ho qoba ho feta 3 mL (Phano ea Subcutaneous ea High-Dose/Volume Biologics, 2021), e beha sepheo, eseng siling e ka finyelloang.
Key Takeaway： Sebaka sa mahloriso se ka khonehang le ho qhibiliha ha 'nete Li-Peptide tsa Synthetic moeli ke lipotso tse lokelang ho arajoa pele sepheo sa tlhahiso se tsitsisoa.
Kopanyo, Boiketsi ba ho Kopanela, Gelation le Fibrillation ka Peptides
Mathata a ho kopanya peptide le viscosity a qala ka sesosa se tšoanang: maemo a phahameng a peptide a mpefatsa tšebelisano ea peptide-peptide mme e ka lebisa phetohong e lumellanang, kopanelo, pula kapa phallo, ka tahlehelo ea ts'ebetso hammoho le chefo le kotsi ea ho itšireletsa mafung (Mokhoa o Mocha oa ho Lokisetsa Peptide Nanosuspensions e tsitsitseng e phahameng ea Concentration, 2023).
Litsela tse peli li bohlokoa, 'me ba batla mekhoa e fapaneng. Colloidal aggregation ke kopano e tsamaisoang ke ho qhibiliha ea limolek'hule tse entsoeng ka tlhaho; conformational aggregation e latela karohano e sa fellang e pepesang libaka tse khomarelang. Chromatography ea boholo-holo (SEC) e rarolla kabo e akaretsang e ipapisitseng le boholo empa e ka sitisa mefuta e ikamahanyang le kholomo ea matrix. Ho hasana ha leseli le matla (DLS) e tlaleha kabo ea boholo ba hydrodynamic, leha maemo a eona a matla a boima a lebisa ho mefuta e meholohali e teng. Thiolavin T (ThT) fluorescence e na le kutloelo-bohloko ho sebopeho sa fibrillar empa ha se tlhahlobo e khethehileng ea boitsebiso. Dichroism e chitja (CD) e latela phetoho ea sebopeho sa bobeli ntle le ho rarolla boholo ba kakaretso. Tlhahlobo ea ultracentrifugation (AUC) e fana ka kabo ea boholo ba karolo ea tharollo ntle le kholomo ea matrix, maemong a tlase.
Gelation le fibrillation ke mekhoa e fapaneng ea ho hloleha ha peptide, e seng ho kopanngoa ha li-antibody. Ke tsela efe e utloahalang bakeng sa tatellano e khethollang hore na qetellong ea tlhoekiso e tlameha ho tlosa eng le hore na phanele ea tokollo e tlameha ho lemoha eng.
Key Takeaway: Peptide nanosuspension e bonts'itse viscosity e tlase ka holimo 100 mg/mL ka nanosuspension ha e ntse e lula e tsitsitse ka lik'hemik'hale le 'meleng, leha bangoli ba na le thahasello mokhoeng oa nanomilling oo ba o hlahlobang (Mokhoa o Mocha oa ho Lokisetsa Peptide Nanosuspensions e tsitsitseng e phahameng ea Concentration, 2023).
Viscosity joalo ka Boitšoaro ba Phallo, Ha se Nomoro e le 'Ngoe
Viscosity ka sebopeho se phahameng sa concentration peptide ke phallo ea phallo, eseng palo. 'Malo o le mong o nkiloeng sebakeng seo ho lebisitsoeng ho sona o ka hlahisa hampe tsela eo tharollo e tla itšoara ka eona, hobane litsamaiso tsa peptide tse tsepamisitsoeng hangata ha se tsa Newton: ponahalo ea viscosity e theoha ha sekhahla sa ho kuta se ntse se phahama, kahoo boleng boo u bo rekotang bo itšetlehile ka sesebelisoa le maemo ao u a lekanyelitseng tlas'a.
Ho tsepamisa maikutlo ke ntho e ka sehloohong e fapaneng. Ka holimo ka ho lekana 100 mg/mL, liphetoho tse nyane tsa mahloriso a peptide li ka hlahisa liphetoho tse sa lekanyetsoang boitšoarong ba phallo, ke ka hona mothinya o lekantsoeng ho pholletsa le mefuta e mengata e o bolellang ho feta ntlha efe kapa efe ho eona. Mokhoa o mong o tlalehiloeng, nanosuspension ea peptide, boloka viscosity tlase holimo 100 mg/mL ha o ntse o tsitsitse ka dikhemikhale le mmeleng (mohlodi). Tšoara seo ka mokhoa o ikhethileng: bangoli ba lekola mokhoa oa nanomilling oo ba nang le thahasello ho ona, kahoo ha se tseko e akaretsang mabapi le tharollo ea peptide nakong eo.
Sephetho se oela ts'ebetsong ea hau, eseng seringe. Molumo oa ho hloekisa, phetisetso ea tahlehelo le ho tlatsa li-fill kaofela li sebetsa ka har'a lifensetere tsa tsona tsa ho kuta le tsa khatello, le moralo o fetisang tekanyo ea ntlha e le 'ngoe o ntse o ka hloleha mehatong eo. Palo ea ~ 10 cP e atisang ho qotsoa bakeng sa ho enta ke mofuta o tloaelehileng o tlalehiloeng libukeng, eseng moeli oa bokahohle. Boitšoaro bo lekantsoe ho pholletsa le mefuta ea mahloriso, eseng sebakeng seo ho shebiloeng feela, ke sona se u bolellang hore na sepheo se ka etsoa kapa che. Tlhahiso ea Peptide
Tšebelisano 'moho, Li-counterions le Container Contact
Khokahano e thusang le buffer ho peptide e nang le maikutlo a holimo e hatelloa ke boitšoaro bo ts'oanang ba boikopanyo bo tsamaisang viscosity.: ho feta moo peptide e sebelisanang le eona, tšebelisano-'moho ea eona le sete ea mothusi e fetoha e sa lebelloang. That is why peptide solubility and excipient compatibility are usually screened together, at the target concentration, ho ena le ka tatellano.
The counterion is part of that formulation, not a purification leftover. Acetate has largely replaced TFA in peptide drug synthesis because TFA was found to negatively impact peptide stability and biological activity. The tolerability signal is peptide-specific rather than general: in one named peptide, the TFA salt of the tetra-branched M33 was 5-30% more cytotoxic toward normal bronchial epithelial cells than its acetate counterpart, and a TFA-containing MOG formulation accelerated encephalomyelitis onset by about 5 days versus controls at comparable incidence and severity. Both are direction-of-effect findings in named systems, not rates that transfer to another sequence.
Sebopeho sa letsoai ha se fetole sebopeho sa covalent kapa ion ea mass-spectrometry, empa e fetola karoloana ea lintho tse lekantsoeng e leng peptide khahlano le counterion. TFA e na le boima bo bongata bo shoeleng sebakeng sa protonated ho feta acetate, kahoo tsela eo letsoai le fetohang ka eona ho lekanngoa boima ho ata ka ho toba ho lokolloa ha lotho. Subcutaneous injection e eketsa thibelo ea ho mamellana le sebaka seo IV e sa e hlokeng, 'me puisano ea ho koaloa ha lijana e eketsa lintlha tse ka bulehang le lipotso tsa papatso maemong a holimo a litlhoko tsa SC.
Sephetho se fihla tlhoekisong: Liphetoho tsa phapanyetsano ea counterion li lekantsoe boima 'me kahoo li lokolle litlhaloso, mme ho qetwa teng, eseng nakong ea tlhahiso.
Teko ea Botsitso ho Tsoelopele ea Ts'ebetso ea Pele
Teko ea botsitso ba peptide ho nts'etsopele ea ts'ebetso ea pele e araba lipotso tse tharo tse fapaneng, 'me ho li kopanya ke hore na data ea botsitso hangata e fihla morao haholo ho fetola eng kapa eng. Pholiso e qobelloang e botsa hore na ke litsela life tsa ho theola seriti tse teng le hore na mokhoa oa ho hlahloba o ka li bona. Liphuputso tse potlakileng li botsa hore na molek'hule e pholoha khatello ea maikutlo eo e ka kopanang le eona ha e sebetsana le ho e tsamaisa. Lithuto tsa nako e telele li botsa hore na bophelo ba sethala ke eng.
ICH Q1A(R2) maemo a kakaretso a beha moralo oa taolo: polokelo ea nako e telele ho 25°C ± 2°C/60% RH ± 5% RH kapa 30°C ± 2°C/65% RH ± 5% RH bakeng sa bonyane ba 12 likhoeli, mahareng ho 30°C ± 2°C/65% RH ± 5% RH bakeng sa 6 likhoeli, mme e potlakile ho 40°C ± 2°C/75% RH ± 5% RH bakeng sa 6 likhoeli, le bonyane ba nako lintlha tsa 0, 3 le 6 likhoeli ka ho potlakisa le 0, 6, 9 le 12 likhoeli moo maemo a mahareng a batloang (Ke Q1A(R2) tataiso, e sebetsang hantle 2003).
Lehlakore la analytical le sebetsa tlas'a litlhoko tse fapaneng. Ho etsa lifoto le ho netefatsa mokhoa li laoloa ke ICH Q1B le Q2(R2) ditlhoko, le phokotso e qobelloang ke eona e qholotsang khetho ea mekhoa: ho fihlela mokhoa o le botsitso-bo bontšang, lipalo tsa tokollo le botsitso li hlalosa tekolo, eseng molek'hule (Ke Q1A(R2) tataiso, 2003).
Hangata lingaka li tsamaisa ho theoloa ka mokhoa o qobelloang e le setsi sa khatello ea maikutlo: mocheso, Qhamisa, tsitsinyeho ea mochini, kganya, le pH e feteletseng. Mekhahlelo e khethehileng ea khatello ea maikutlo e sebelisitsoeng hohle tšimong e tsoa mehloling e ke keng ea netefatsoa hape bakeng sa sengoloa sena, kahoo tšoara phanele eo e le kopano e sebetsang ho e-na le protocol e qotsitsoeng; mekhahlelo e teng ka lebaka la mokhoa oa hau oa ntlafatso.
Sephetho sa ntlafatso ea ts'ebetso ke ho laela. Mokhoa o bontšang botsitso o tlameha ho ba teng pele ho lokolloa kapa data ea botsitso e bolela eng kapa eng, e behang nts'etsopele ea mokhoa holimo ho senotlolo sa tlhahiso, eseng kamora eona.
Ke Eng e Lokelang ho Arajoa Sethaleng sa Synthesis le Tlhoekiso Pele Moetso o Lokela
Lipotso tsa nts'etsopele tse tlamehang ho koaloa pele ho senotlolo sa tlhahiso li khutšoanyane, lenane le itseng: sebaka se ka khonehang sa mahloriso, moeli oa 'nete oa ho qhibiliha, hore na molek'hule e ikamahanya le eona ha mahloriso a phahama, hore na viscosity e fetoha joang ho pholletsa le sebaka seo, le seo letsoai le se etsang ho leka-lekana ho qhibiliha, botsitso le tshebetso. E 'ngoe le e 'ngoe ke thepa ea lithethefatsi, 'me e' ngoe le e 'ngoe e theko e tlaase ho lekanya pele sepheo sa tlhahiso e tsitsitsoe ho feta ka morao.
Mokhoa oa ho hloleha khafetsa ke oa tatellano. Sepheo sa tlhahiso se beoa pele, joale ntho ea lithethefatsi e khetholloa bakeng sa thepa eo sepheo se itšetlehileng ka eona. Ha karabo e khutla e sa rateheng, lenaneo le ntse le buisana le palo eo le seng le itlamme ka eona.
Ho ikamahanya le uena ho lokeloa ke tlhokomelo ea pele ka lebaka la ts'ebetso hammoho le mokhoa oa ho theha. At high concentration it can slow ultrafiltration and diafiltration enough to become unacceptable at process scale, which turns a solution-phase behaviour into a manufacturing constraint.
Closing these questions earlier is a workflow change rather than a new technique. It moves characterisation into synthesis and purification, where salt-form and counterion decisions are still open, and where a partner supporting peptide chemistry and manufacturing can help sequence the work.
Maikutlo a Tloaelehileng a Fosahetseng Mabapi le Tsoelo-pele ea Peptide e Phahameng
Five assumptions carried over from mAb work cause most of the trouble in a high-concentration peptide formulation. Each one is testable, and each has a method that settles it. About
That peptide aggregation behaves like antibody aggregation. Ha ho joalo. Antibodies aggregate around a folded core that can be destabilised and then re-stabilised; li-peptide ha li na motheo o joalo, kahoo ho leka-lekana ha tsela ho fetohela ho aggregation e tsamaisoang ke mahloriso le gelation, moo mahloriso ka bowona e leng phetoho ya ho kganna. chromatography ea boholo-holo le analytical ultracentrifugation li arola mefuta; mochine o tlameha ho hlalosoa ho latela hore na kabo e tsamaea joang ka mahloriso, ha u bale mofuta oa antibody.
Nomoro eo e le 'ngoe ea viscosity e khetholla tsamaiso. Tekanyo e le 'ngoe ka lebelo le le leng la ho kuta e ke ke ea khetholla tharollo ea Newtonian ho e fokotsang ho kuta. Moo nanosuspension e tlalehiloeng ka viscosity e tlase ka holimo 100 mg/mL, sephetho seo ke sa sistimi e hasantsoeng le mokhoa o sebelisitsoeng, eseng ho li-peptide tse phahameng haholo ka kakaretso.
Hore buffer e nang le antibody e tla tšoara peptide. Motsoako o hlakileng oa peptide o itšetlehileng ka pH o bolela hore sebopeho sa pH se khethiloeng bakeng sa botsitso ba protheine se ka lula moeling oa lefika bakeng sa peptide..
Hore counterion ke lintlha tsa tlhoekiso. Sebopeho sa letsoai se fetola boima bo lekantsoeng 'me se amahanngoa le phapang ea botsitso le mamello.
Teko eo ea botsitso ke mosebetsi oa morao-rao. Mokhoa o bonts'ang botsitso o tlameha ho ba teng pele ho notleloa, kapa ha ho letho leo u ka notlelang khahlanong le lona.
⚠️ Tlhokomeliso: Mokhoa o iphetang ka morao ho tse hlano ke sepheo sa tlhahiso e behiloeng pele motsoako oa lithethefatsi o khetholloa bakeng sa thepa eo sepheo se itšetlehileng ka eona..
Mehato e Latelang
Qeto ea tsela ha se khetho ea liphutheloana tsa morao-rao. E phatlalatsa morao ka lenaneo lohle: moralo oa tatellano, tlhaho, tlhoekiso, Letsoai le lotho li lokolla litlhoko tsohle tsa thepa tseo sepheo sa subcutaneous se behang, and each of them is cheaper to answer before the formulation locks than after.
That is the reframe worth keeping from this guide. The IV to subcutaneous peptide manufacturing shift changes the specification the molecule has to meet, and the six question clusters above are the places where that specification is actually decided. Peptide stability testing in early process development sits at the end of that chain, but it verifies decisions made much earlier.
A practical first step is small. Take the question list in this guide and walk it against the analytical and lot-release documentation package you already hold, or raise a difficult sequence with a technical team before the formulation is fixed. MOL Changes e phatlalatsa e le morekisi oa peptide ea nang le thahasello ea khoebo ho litekanyetso tsa boleng ba peptide. Decisions about a specific molecule or program require qualified formulation, kahlolo ea taolo le ea kliniki; sengoloa sena ke semelo sa tekheniki, eseng keletso e khethehileng ea lenaneo.
Lipotso Tse Botsoang Khafetsa
Hobaneng ho tloha ho IV ho ea ho subcutaneous ho fetola ntho ea lithethefatsi ho fapana le sesebelisoa feela?
Hobane phetoho ea tsela e tiisa mokhoa oo molek'hule o lokelang ho kopana le ona, eseng seringe seo e tsamaeang ka sona. Subcutaneous delivery caps bophahamo ba modumo, 'me kepisi eo e fetola ka kotloloho tlhoko ea mahloriso eo motsoako oa moriana o lokelang ho o khotsofatsa. Infusion ea IV ha e na siling e ka bapisoang, kahoo lenaneo le ka jara tharollo ea dilute ka nts'etsopele ntle le ho tobana le solubility, viscosity kapa meedi ya ho ikamanya. Hang ha molumo o tsitsitse, meeli eo e fetoha thepa ea lithethefatsi, ho buuoa ka mokhoa oa letsoai, counterion, tlhoekiso ea qetello le moralo oa tatellano ho e-na le ho etsoa feela.
Ke "subcutaneous peptide formulation" e hlileng e hlokang mahloriso afe?
Concentration ke boima ba lethal dose bo arotsoeng ka molumo oa ente, kahoo sepheo se latela lipalo ho tloha siling ea sesebelisoa: a 100 mg tekanyo ka a 1 ente ea mL e hloka 100 mg/mL, le tekanyo e tšoanang ka 0.5 mL e hloka 200 mg/mL. Hobane liente tsa SC li lekanyelitsoe ho tekanyo ea tekanyo ea 1-1.5 mL, li-peptide tse kentsoeng ka holimo kapa holimo 100 mg hangata e lula holimo 100 mg/mL (Journal of Pharmaceutical Sciences). Palo e nepahetseng e itšetlehile ka tekanyo ea hau le sesebelisoa, empa lipalo ha li buisanoe.
Hobaneng ho le thata ho laola ho qhibiliha ha peptide ho feta ho qhibiliha ha antibody maemong a holimo?
Li-peptide ha li na li-antibodies tsa mantlha tse phuthoang tsa hydrophobic tse sebelisoang ho pata liketane tsa mahlakoreng a se nang polar, kahoo masala ao a lula a pepesitsoe holimo 'me a khanna mokhatlo. Liphello tse sebetsang ke ho qhibiliha ho itšetlehileng ka pH: fensetere e ka sebelisoang e patisane ho feta protheine e mennweng, 'me e fetoha ka matla a ionic le counterion. Boholo bo itšetlehile ka tatelano, kahoo moralo o alimiloeng ho nts'etsopele ea mAb o tla bolela hampe moo peptide e fanoeng e bang e sa sebetseng.
Ke mekhoa efe ea tlhahlobo e fumanang pokello ea peptide, mme e mong le e mong o haellwa ke eng?
Mokhoa o latela tsela eo u hlokang ho e tšoaea. Chromatography e sa kenyelletsoeng boholo e rarolla kabo e akaretsang e ipapisitseng le boholo empa e ka sitisa tekano eo e e lekanyang.. Khaso ea mabone a matla e tlaleha kabo ea boholo bo boima ba hydrodynamic, e sekametseng ho mefuta e meholo mme e ka fosa dioligomer tse nyane. ThT fluorescence e tsotella sebopeho sa fibrillar empa ha se tlhahlobo e khethehileng ea boitsebiso. Circular dichroism e tlaleha litaba tsa sebopeho sa bobeli ntle le ho rarolla boholo ba kakaretso. Analytical ultracentrifugation e fana ka kabo ea boholo ba karolo ea tharollo ntle le tšebelisano ea kholomo, ka litšenyehelo tsa ho feta. Ha ho mokhoa o le mong o koahelang litsela tsohle; data ea orthogonal ke maemo.
Ke tekanyo e le 'ngoe ea viscosity e lekaneng ho khetholla peptide e phahameng haholo?
Che. Tekanyo ea ntlha e le 'ngoe e nka boitšoaro ba Newtonian, 'me litharollo tse phahameng tsa peptide hangata ha se Newtonian, kahoo motho ea balang a ka bua hampe kamoo boitsebiso bo itšoarang kateng nakong ea ho sefa, fetisa le ho tlatsa-qeta. Ho e-na le hoo, lekanya lebelo la ho phalla ho pholletsa le mefuta ea mahloriso, le ho tlaleha maemo a ho kuta hammoho le sephetho.
Na counterion e hlile e bohlokoa bakeng sa sethethefatsi sa peptide?
Ee. The counterion e etsa qeto ea hore na ke karolo efe ea thepa e lekantsoeng e leng peptide khahlano le counterion, e fetolang mahloriso a sebetsang hantle ao u a etsang le tikoloho ea ionic eo molek'hule e e bonang. Trifluoroacetate e fane haholo ka acetate ka har'a lithethefatsi tsa peptide ka lebaka lena, 'me khetho e ata ho taolo ea pH, solubility le mamello ea sebakeng seo sebakeng sa ente. Ke qeto ea ho sebelisa lithethefatsi, eseng lintlha tsa tlhoekiso.
Ke lithuto life tsa botsitso tse hlokahalang pele tlhahiso e notlella?
Ka bonyane, ICH Q1A(R2) maemo a kakaretso le lintlha tse fokolang tsa nako, e sebelisoa ho motsoako oa lithethefatsi le tlhahiso e sisintsoeng. Ts'ebetso ea pele ea ts'ebetso e boetse e lokela ho kenyelletsa mosebetsi oa ho theola boima ba 'mele ho tseba litsela tseo mokhoa oa hau o bonts'ang botsitso o lokelang ho li rarolla.. Sephutheloana se netefatsa ho solubility, aggregation le viscosity menahano e entsoeng pejana; haeba e sa khone ho fumana tsela, monahano o dula o sa netefatswa.
Qetello
Phetoho ea tlhahiso ea IV ho subcutaneous peptide ke, tlase, qeto e khethehileng: tsela eo u e khethang e ngola bocha hore na molek'hule e lokela ho ba eng, e seng feela kamoo e fanoang kateng. Tlhoko ea ho tsepamisa maikutlo, li-peptide tsa siling tsa solubility li fihla pele ho li-antibodies, ho ikopanya le litsela tsa ho ikamahanya, boitšoaro ba ho phalla ho pholletsa le mefuta ea mahloriso, excipient le counterion tshebeletsano, 'me sephutheloana sa botsitso se netefatsang tsohle ke lipotso tse tšeletseng tse hlahang hammoho ha lenaneo le fetela ho SC dosing.. E 'ngoe le e' ngoe e theko e tlaase ho e araba ka ho kopanya le ho hloekisa ho feta ka mor'a liloko tse entsoeng.
Tsela ea leeto ha e na khoao. Ho fana ka subcutaneous ho 'nile ha kopanngoa ka lilemo ho pholletsa le baeloji, 'me ha mefuta le lifomate tsa lisebelisoa li ntse li tsoela pele ho fetoha, litlhoko tseo ba li behang li tla 'ne li tsoele pele ho ea holimo ho moralo oa lithethefatsi. Mananeo a nkang phetoho ea tsela e le bothata ba morao-rao ba ho qapa, a tla lula a fumana hore e ne e le tatellano, letsoai-form le tlhoekiso-endpoint bothata nako eohle.
MOL Changes e phatlalatsa thepa ena e le morekisi oa peptide ea nang le thahasello ea khoebo ho litekanyetso tsa boleng ba peptide..
